A 22-year-old Village of Pewaukee man who was under the influence of illegal drugs when he hit a jogger with his vehicle in November has been sentenced to 13 years in prison.
Thomas Brinkman struck Greg Phelps, 45, on Nov. 28 while Phelps was running on a sidewalk along Capitol Drive in the Village of Pewaukee. The impact broke 14 bones in Phelps' body, lacerated his liver and caused significant bleeding in his brain.
In June, Brinkman entered guilty pleas to injury by intoxicated use of a vehicle and possession of narcotic drugs and was convicted by Waukesha County Circuit Court James R. Kieffer. As part of a plea agreement, charges of reckless driving-causing great bodily harm, injury by use of a vehicle while under the influence of controlled substance and possession of cocaine were dismissed.
Cocaine and an anti-anxiety drug were detected in Brinkman's bloodstream, according to court records.
A hypodermic needle was found stuffed in his pants, and Brinkman told police he used heroin the day before the crash and maybe that day, the criminal complaint says.
In addition to the 13 years in prison, Kieffer on Friday ordered Brinkman to serve five years of extended supervision when he is released from prison.
Kieffer also ordered the sentenced to be served after Brinkman has completed 3 ½-year prison term he was sentenced to in May 2009 years in prison for being part of a heroin ring in Milwaukee and Waukesha counties.
Brinkman was among 27 people from Milwaukee, Chicago and Waukesha County who had been charged in July in federal court as part of a drug ring that authorities say led to 11 overdoses, five of them fatal. Brinkman was not tied to any of the deaths.
And the federal case against Brinkman was dismissed in March 2009 after he agreed to plead guilty in Waukesha County to a state heroin charge.
Although he had been sentenced to prison on that charge, he was released in 2010 after he was determined not to be a violent offender.
But his probation was revoked after he struck Phelps and he was sent back to prison.
2011年4月14日星期四
Artificial pancreas ready for diabetics to try at home, say research scientists
Trials of an artificial pancreas that can monitor the blood sugar levels of people with diabetes and then deliver insulin more accurately should move out of hospital into homes as soon as possible, funders of the research programme say.
Promising evidence that adults may be better able to control their condition overnight has emerged from a Cambridge University-led study involving 24 adults and using developments of existing technologies. It was funded by the charity Diabetes UK, and follows encouraging research using similar equipment on pregnant mothers and children with Type 1 diabetes.
Type 1 usually strikes people before they are 40 years of age and affects about one in 10 of those with diabetes. They need to test their own blood sugar levels regularly before injecting themselves with insulin or setting a pump which releases the hormone via a cannula under the skin.
The new system involves placing a small circular patch on the body which continuously monitors glucose levels, sending the results by radio signals to the insulin pump which then automatically delivers the appropriate amount of insulin. This should reduce the incidence of "hypos", when blood sugar levels fall too low, possibly rendering a person unconscious or causing unpleasant symptoms, including sweating, tingling in the lips and a pounding heart.
The latest tests, involving 10 men and 14 women aged 18-65, suggested a 22% improvement in the time participants kept their blood glucose levels in a safe range, halving the time they spent with low blood-glucose levels and reducing the risk of both short- and long-term complications. Half the participants were monitored overnight after consuming a medium-sized meal and the others after a larger meal and alcohol.
Dr Roman Hovorka, who led the research, said: "Hypoglycaemia remains a major challenge, especially during the night, so it's encouraging to see such promising results from our trial using commercially available devices.
"The study is a stepping stone to testing the artificial pancreas at home and suggests that the artificial pancreas may be suitable in adults as well as in children and adolescents we found previously." Iain Frame, head of research at Diabetes UK, said: "The improvements in glucose control overnight using this new technology are impressive, and it is good to see this work develop with the addition of testing the effects following a meal with some wine.
"We now need to see an extension of this study, one which tests larger numbers of people, and then take it out of the hospital and in to the home setting."
Promising evidence that adults may be better able to control their condition overnight has emerged from a Cambridge University-led study involving 24 adults and using developments of existing technologies. It was funded by the charity Diabetes UK, and follows encouraging research using similar equipment on pregnant mothers and children with Type 1 diabetes.
Type 1 usually strikes people before they are 40 years of age and affects about one in 10 of those with diabetes. They need to test their own blood sugar levels regularly before injecting themselves with insulin or setting a pump which releases the hormone via a cannula under the skin.
The new system involves placing a small circular patch on the body which continuously monitors glucose levels, sending the results by radio signals to the insulin pump which then automatically delivers the appropriate amount of insulin. This should reduce the incidence of "hypos", when blood sugar levels fall too low, possibly rendering a person unconscious or causing unpleasant symptoms, including sweating, tingling in the lips and a pounding heart.
The latest tests, involving 10 men and 14 women aged 18-65, suggested a 22% improvement in the time participants kept their blood glucose levels in a safe range, halving the time they spent with low blood-glucose levels and reducing the risk of both short- and long-term complications. Half the participants were monitored overnight after consuming a medium-sized meal and the others after a larger meal and alcohol.
Dr Roman Hovorka, who led the research, said: "Hypoglycaemia remains a major challenge, especially during the night, so it's encouraging to see such promising results from our trial using commercially available devices.
"The study is a stepping stone to testing the artificial pancreas at home and suggests that the artificial pancreas may be suitable in adults as well as in children and adolescents we found previously." Iain Frame, head of research at Diabetes UK, said: "The improvements in glucose control overnight using this new technology are impressive, and it is good to see this work develop with the addition of testing the effects following a meal with some wine.
"We now need to see an extension of this study, one which tests larger numbers of people, and then take it out of the hospital and in to the home setting."
订阅：
博文 (Atom)